1. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
- Author
-
Kenzo Hiroshima, Ikuo Sekine, Hideaki Shimada, Masato Shingyoji, Koichiro Tatsumi, Yuji Tada, Takao Namiki, Kengo Shimazu, Masatoshi Tagawa, and Takao Morinaga
- Subjects
0301 basic medicine ,Mesothelioma ,p53 ,Cancer Research ,Nutlin-3a ,Lung Neoplasms ,Antineoplastic Agents ,Pharmacology ,lcsh:RC254-282 ,Piperazines ,03 medical and health sciences ,0302 clinical medicine ,Western blot ,Cell Line, Tumor ,Genetics ,medicine ,Humans ,PI3K/AKT/mTOR pathway ,Cell Proliferation ,Gene knockdown ,Mammalian target of rapamycin ,medicine.diagnostic_test ,business.industry ,Cell growth ,TOR Serine-Threonine Kinases ,Cell Cycle ,Mesothelioma, Malignant ,Imidazoles ,Cell cycle ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Metformin ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Signal transduction ,Tumor Suppressor Protein p53 ,business ,Immortalised cell line ,medicine.drug ,Research Article ,Signal Transduction - Abstract
Background Mesothelioma is resistant to conventional treatments and is often defective in p53 pathways. We then examined anti-tumor effects of metformin, an agent for type 2 diabetes, and combinatory effects of metformin and nutlin-3a, an inhibitor for ubiquitin-mediated p53 degradation, on human mesothelioma. Methods We examined the effects with a colorimetric assay and cell cycle analyses, and investigated molecular events in cells treated with metformin and/or nutlin-3a with Western blot analyses. An involvement of p53 was tested with siRNA for p53. Results Metformin suppressed cell growth of 9 kinds of mesothelioma including immortalized cells of mesothelium origin irrespective of the p53 functional status, whereas susceptibility to nutlin-3a was partly dependent on the p53 genotype. We investigated combinatory effects of metformin and nutlin-3a on, nutlin-3a sensitive MSTO-211H and NCI-H28 cells and insensitive EHMES-10 cells, all of which had the wild-type p53 gene. Knockdown of p53 expression with the siRNA demonstrated that susceptibility of MSTO-211H and NCI-H28 cells to nutlin-3a was p53-dependent, whereas that of EHMES-10 cells was not. Nevertheless, all the cells treated with both agents produced additive or synergistic growth inhibitory effects. Cell cycle analyses also showed that the combination increased sub-G1 fractions greater than metformin or nutlin-3a alone in MSTO-211H and EHMES-10 cells. Western blot analyses showed that metformin inhibited downstream pathways of the mammalian target of rapamycin (mTOR) but did not activate the p53 pathways, whereas nutlin-3a phosphorylated p53 and suppressed mTOR pathways. Cleaved caspase-3 and conversion of LC3A/B were also detected but it was dependent on cells and treatments. The combination of both agents in MSTO-211H cells rather suppressed the p53 pathways that were activated by nutrin-3a treatments, whereas the combination rather augmented the p53 actions in NCI-H28 and EHMES-10 cells. Conclusion These data collectively indicated a possible interactions between mTOR and p53 pathways, and the combinatory effects were attributable to differential mechanisms induced by a cross-talk between the pathways. Electronic supplementary material The online version of this article (doi:10.1186/s12885-017-3300-y) contains supplementary material, which is available to authorized users.
- Published
- 2017